Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 7/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31109279 | 0.88 | MEN1 (0.37) | ALDH1A1FFAR1LMNAMAPT | |
| SCHEMBL31109238 | 0.76 | MEN1 (0.41) | KEAP1NFE2L2ALDH1A1FFAR1KDM4E | |
| SCHEMBL31109311 | 0.72 | KMT2A (0.39) | KEAP1NFE2L2ALDH1A1FFAR1LMNA | |
| SCHEMBL20545830 | 0.72 | CTSA (0.45) | CTSACYP26A1FFAR1 | |
| SCHEMBL20546319 | 0.71 | CTSA (0.36) | ATML3MBTL1CTSAALDH1A1KDM4E | |
| SCHEMBL20545499 | 0.71 | ALDH1A1 (0.39) | ATML3MBTL1CTSAALDH1A1CYP26A1 | |
| SCHEMBL20546334 | 0.71 | FFAR1 (0.36) | ATML3MBTL1CTSAFFAR1 | |
| SCHEMBL29219680 | 0.71 | CTSA (0.42) | CTSA | |
| SCHEMBL20546304 | 0.71 | CTSA (0.42) | CTSA | |
| SCHEMBL20546056 | 0.71 | FFAR1 (0.44) | L3MBTL1FFAR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615515-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Aviara Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018209363-A2 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180312498-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246451-B2 | Propionic acid derivatives and methods of use thereof | ITGA4, ITGB3, ITGB5 | ATM 4539/4885L3MBTL1 3880/4885CTSA 2586/4885 |
| US-20190225602-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB4 | ATM 4644/4885L3MBTL1 3328/4885CTSA 2468/4885 |
| US-20180312498-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGA4, ITGB3, ITGB5 | ATM 4539/4885L3MBTL1 3880/4885CTSA 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.